Single Center, Phase 2B, Randomized, Double-Blind, Placebo, Individual Components, and 2-Doses, Controlled Pilot Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 in the Acute Treatment of Migraine (ANODYNE-1)
Phase of Trial: Phase II/III
Latest Information Update: 23 Mar 2018
At a glance
- Drugs ALLOD 2 (Primary)
- Indications Migraine
- Focus Proof of concept; Therapeutic Use
- Acronyms ANODYNE1
- Sponsors Allodynic Therapeutics
- 18 Feb 2018 Status changed from recruiting to completed.
- 31 Dec 2017 Planned End Date changed from 1 Apr 2018 to 1 May 2018.
- 31 Dec 2017 Planned primary completion date changed from 1 Feb 2018 to 12 Feb 2018.